Akari Therapeutics, Plc (AKTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
75/76 Wimpole Street
London, FL W1G 9RT
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 8004 0270
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
January 06, 2014
| Name | Title | Pay | Year Born |
| Abizer Gaslightwala | Chief Executive Officer, President & Director | 476,149 | 1974 |
| Kameel D. Farag | Interim Chief Financial Officer | 251,493 | 1979 |
| Satyajit Mitra | Executive Director & Head of Oncology | 0 | 1975 |
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.